Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combinations vs DPd in relapsed/refractory multiple myeloma
NCT05455320Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Oct 2022; status: active, not recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05455320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455320.